The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Lilly; Novartis; Pfizer; Pierre Fabre; Roche
Speakers' Bureau - AstraZeneca; Daiichi Sankyo; Lilly; Novartis; Pfizer; Pierre Fabre; Roche
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Lilly; Novartis; Pfizer; Pierre Fabre; Roche
Addition of the MUC-1 vaccine tecemotide to neoadjuvant systemic therapy for patients with early breast cancer: Survival results from the prospective randomized ABCSG 34 trial.
 
Christian F. Singer
Honoraria - AstraZeneca/MedImmune; Daiichi Sankyo Europe GmbH; Novartis
Consulting or Advisory Role - AstraZeneca/MedImmune; Daiichi-Sanyko; Gilead Sciences; Novartis; Sanofi/Aventis
Speakers' Bureau - AstraZeneca/MedImmune; Novartis
Research Funding - Amgen; Amgen; AstraZeneca/MedImmune; Myriad Genetics; Novartis; Roche; Sanofi
Travel, Accommodations, Expenses - Daiichi-Sankyo; Gilead Sciences; Novartis; Roche
 
Dominik Hlauschek
Research Funding - Amgen (Inst); Amgen (Inst); Artera (Inst); AstraZeneca (Inst); Bristol Myers Squibb (Inst); Cepheid (Inst); Daiichi Sankyo (Inst); Novartis (Inst); OncoMark (Inst); Pfizer (Inst); Roche (Inst); Sandoz (Inst)
 
Georg Pfeiler
Honoraria - Accord Healthcare; Amgen; AstraZeneca/Daiichi Sankyo; AstraZeneca/Merck; Gilead Sciences; Lilly; Menarini; Novartis; Pfizer; Roche/Genentech; Seagen; UCB
Consulting or Advisory Role - Amgen; AstraZeneca/Daiichi Sankyo; AstraZeneca/Merck; Gilead Sciences; Lilly; Menarini; Novartis; Pfizer; Roche/Genentech; Seagen; UCB
Speakers' Bureau - Accord Healthcare; Amgen; AstraZeneca/Daiichi Sankyo; AstraZeneca/Merck; Gilead Sciences; Lilly; Novartis; Pfizer; Roche/Genentech; Seagen; UCB
Research Funding - Accord Healthcare; AstraZeneca (Inst); Pfizer; Roche/Genentech
Travel, Accommodations, Expenses - Accord Research; AstraZeneca/Daiichi Sankyo; Gilead Sciences; Lilly; Lilly; Merck; Novartis; Pfizer; Roche/Genentech; Seagen
 
Daniel Egle
Honoraria - AstraZeneca; Daiichi Sankyo; Gilead Sciences; Lilly; Novartis; Pfizer; Roche; Seagen; Sirius Medical
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Gilead Sciences; Lilly; Novartis; Pfizer; Roche; Seagen; Sirius Medical
Research Funding - Sirius Medical
Expert Testimony - Seagen
Travel, Accommodations, Expenses - Daiichi Sankyo; Novartis; Pfizer; Roche
 
Rupert Bartsch
Honoraria - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Lilly
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Eisai; Lilly
Research Funding - Daiichi Sankyo (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo; Merck Sharp & Dohme; Novartis; Pfizer
 
Christoph Suppan
No Relationships to Disclose
 
Angelika Pichler
Research Funding - Abbvie
 
Edgar Petru
Honoraria - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Roche
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca; Roche
Travel, Accommodations, Expenses - AstraZeneca/Daiichi Sankyo; Roche
 
Richard Greil
Stock and Other Ownership Interests - Lilly (Inst); Novo Nordisk (Inst)
Honoraria - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Gilead Sciences; Merck; MSD; Novartis; Roche; Sandoz; Sanofi; Takeda
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Gilead Sciences; Janssen; Merck; MSD; Novartis; Roche; Sanofi; Takeda
Research Funding - Abbvie; Abbvie; Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo Europe GmbH (Inst); Gilead Sciences (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Roche (Inst); Sandoz (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Gilead Sciences; Janssen-Cilag; MSD; Novartis; Roche
 
Margaretha Rudas
No Relationships to Disclose
 
Michael Seifert
Consulting or Advisory Role - Gilead Sciences
Travel, Accommodations, Expenses - Novartis; Pfizer; Roche
 
Andreas Petzer
Honoraria - Abbvie; Amgen; AstraZeneca; Celgene/Bristol-Myers Squibb; Janssen; Kite/Gilead; Novartis; Pfizer; Roche; Sandoz; Sanofi; Seagen; Takeda
Consulting or Advisory Role - Abbvie; AstraZeneca; Daiichi Sankyo; Janssen; Kite/Gilead; Novartis; Pfizer; Roche; Sanofi; Seagen; Takeda
Travel, Accommodations, Expenses - Daiichi Sankyo; Gilead Sciences; Janssen; Lilly; Pierre Fabre; Roche
 
Florian Fitzal
Honoraria - AstraZeneca; Novartis; Roche
Consulting or Advisory Role - AstraZeneca; Roche
Expert Testimony - Merck Sharp & Dohme
Travel, Accommodations, Expenses - AstraZeneca; Novartis; Roche
 
Zsuzsanna Bago-Horvath
Honoraria - AstraZeneca; Gilead Sciences; Merck Sharp & Dohme
Consulting or Advisory Role - AstraZeneca; Gilead Sciences; Stemline Therapeutics
Expert Testimony - AstraZeneca
 
Martin Filipits
Honoraria - AstraZeneca; Bio-Rad; Boehringer Ingelheim; Lilly; Merck; Novartis
 
Lidija Soelkner
No Relationships to Disclose
 
Christian Fesl
Research Funding - Amgen (Inst); Pfizer (Inst)
 
Michael Gnant
Employment - Sandoz (I)
Honoraria - Amgen; AstraZeneca; Daiichi Sankyo Europe GmbH; EPG Health; Lilly; Menarini; MSD; Novartis; Pierre Fabre
Consulting or Advisory Role - AstraZeneca; Daiichi-Sankyo; Lilly; Menarini; MSD Oncology; Novartis; Veracyte
Expert Testimony - Lilly; Veracyte
Travel, Accommodations, Expenses - Lilly; Novartis
Other Relationship - ABCSG GmbH; ABCSG Research Services GmbH